India considers price controls for patented drugs
India is planning to rein in prices of expensive patented drugs to make medicines affordable to its predominantly poor population, a top government official said on Friday.
Govt defers decision on M&M, Pfizer FDI applications
Government has deferred decision on Mahindra group's proposal to bring in FDI for a defence production joint venture and on another application by pharma major Pfizer to bring in foreign equity in a c
Biocon, Pfizer call off $350 mn pact on insulin products
Biocon and US drug major Pfizer on Tuesday called off USD 350 million global alliance to commercialise the Bangalore-based firm's biosimilar versions of insulin and insulin analog products.
"The comp
Biocon Q2 net drops as energy costs, wages rise
Biocon Ltd, India top biotechnology company, reported a 4 per cent drop in quarterly profit due to higher energy costs and rise in wages, but said strong demand from branded formulations offered oppor
DRL may contest Pfizer patent suit
Jan. 5: Dr Reddy’s Laboratories (DRL) is likely to contest a patent infringement case filed against it by global pharma giant Pfizer over its cholesterol lowering drug atorvastatin.
Dr Reddy’s had fi